The ALB Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population of A-549 cells carrying a targeted disruption of the ALB gene. This loss-of-function model is generated in the Homo sapiens A-549 lung adenocarcinoma cell line, providing a versatile tool for investigating albumin biology in a non-hepatic epithelial context. The polyclonal format ensures a heterogeneous mixture of edited alleles, offering robust average knockout effects suitable for pooled functional screens and population-level studies.
The A-549 cell line, established from a 58-year-old Caucasian male with lung adenocarcinoma, displays an adherent epithelial morphology and is widely employed as a model of alveolar type II epithelium. These cells are extensively utilized in cancer biology, drug metabolism, and respiratory infection research, making them a well-characterized platform for dissecting molecular mechanisms in pulmonary and systemic disease contexts.
ALB encodes serum albumin, the predominant plasma protein responsible for maintaining colloidal osmotic pressure and serving as a primary carrier for hydrophobic ligands, including fatty acids, bilirubin, hormones, and various pharmaceuticals. Albumin functions downstream of transcriptional regulators such as HNF1, HNF4, C/EBP??, FOXA2, and the glucocorticoid receptor. It interacts with numerous molecular partners, including fatty acids, calcium ions, SPARC, megalin, cubilin, and the FcRn receptor, to modulate ligand bioavailability, antioxidant defense, and vascular permeability.
Since A-549 cells do not endogenously express albumin, this knockout model creates a null background for studying exogenously introduced albumin variants or assessing off-target interactions of albumin-binding compounds. The loss of ALB in this non-physiological context allows dissection of albumin??s role in drug pharmacokinetics, oncotic pressure-independent signaling, and tumor microenvironment modulation without confounding endogenous protein. It is particularly valuable for control experiments in immunoassays and for evaluating albumin-mediated transport in lung epithelial biology.
Typical applications include use as a negative control in western blotting, ELISA, and immunocytochemistry to validate albumin detection reagents. The cells are ideal for overexpressing wild-type or mutant albumin constructs to study trafficking, secretion, and ligand-binding properties. Additionally, they are suited for drug uptake and efflux studies, pharmacokinetic profiling of albumin-binding therapeutics, and investigation of albumin??s antioxidant functions in epithelial injury models. For further inquiries regarding this product, please contact Ascent Research.
